This company has been marked as potentially delisted and may not be actively trading. Tenzing Acquisition (TZAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TZAC vs. TAOX, MTNB, OBSV, AEON, NRBO, SPRB, AEZS, CPHI, GRAY, and OGENShould you be buying Tenzing Acquisition stock or one of its competitors? The main competitors of Tenzing Acquisition include Synaptogenix (TAOX), Matinas Biopharma (MTNB), ObsEva (OBSV), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), Spruce Biosciences (SPRB), Aeterna Zentaris (AEZS), China Pharma (CPHI), Graybug Vision (GRAY), and Oragenics (OGEN). Tenzing Acquisition vs. Its Competitors Synaptogenix Matinas Biopharma ObsEva AEON Biopharma NeuroBo Pharmaceuticals Spruce Biosciences Aeterna Zentaris China Pharma Graybug Vision Oragenics Synaptogenix (NASDAQ:TAOX) and Tenzing Acquisition (NASDAQ:TZAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Which has more volatility & risk, TAOX or TZAC? Synaptogenix has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Tenzing Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Does the media favor TAOX or TZAC? In the previous week, Synaptogenix had 1 more articles in the media than Tenzing Acquisition. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Tenzing Acquisition. Synaptogenix's average media sentiment score of 0.00 equaled Tenzing Acquisition'saverage media sentiment score. Company Overall Sentiment Synaptogenix Neutral Tenzing Acquisition Neutral Which has stronger valuation and earnings, TAOX or TZAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$20.16-0.38Tenzing AcquisitionN/AN/A$620KN/AN/A Do institutionals and insiders have more ownership in TAOX or TZAC? 10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 60.9% of Tenzing Acquisition shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 37.5% of Tenzing Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TAOX or TZAC more profitable? Tenzing Acquisition's return on equity of -13.32% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -277.76% -150.79% Tenzing Acquisition N/A -13.32%-1.36% SummaryTenzing Acquisition beats Synaptogenix on 5 of the 7 factors compared between the two stocks. Get Tenzing Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TZAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TZAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TZAC vs. The Competition Export to ExcelMetricTenzing AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$2.76M$834.78M$2.09B$9.61BDividend YieldN/A4.84%13.78%4.10%P/E RatioN/A1.1812.2826.05Price / SalesN/A26.352,765,917.02103.68Price / Cash143.1019.5657.5158.48Price / Book0.556.643.076.61Net Income$620K-$4.94M-$456.46M$265.65M Tenzing Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TZACTenzing AcquisitionN/A$0.54+3.6%N/A-38.7%$2.76MN/A0.00N/AHigh Trading VolumeTAOXSynaptogenixN/A$6.93-0.4%N/AN/A$9.67MN/A-0.344Earnings ReportGap UpMTNBMatinas Biopharma0.6941 of 5 stars$1.74+2.4%N/AN/A$8.85MN/A-0.3630OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap DownAEONAEON Biopharma2.9022 of 5 stars$0.69-5.0%$360.00+51,750.8%-98.9%$7.85MN/A3.865Gap DownNRBONeuroBo PharmaceuticalsN/A$0.64-1.6%N/A-82.5%$5.51MN/A0.0010SPRBSpruce Biosciences2.3423 of 5 stars$8.92-0.4%$131.25+1,372.2%-75.2%$5.01M$4.91M-9.4820Gap DownAEZSAeterna ZentarisN/A$2.63-9.0%N/A-55.3%$4.72M$2.37M-0.1820High Trading VolumeCPHIChina PharmaN/A$1.43+1.1%N/A-93.2%$4.67M$4.40M0.00250Gap UpGRAYGraybug VisionN/A$2.94+1.1%N/A-33.3%$4.62MN/A-1.7027Positive NewsHigh Trading VolumeOGENOragenics0.1204 of 5 stars$1.08+1.9%N/A-95.9%$4.46MN/A-0.155Short Interest ↓ Related Companies and Tools Related Companies Synaptogenix Competitors Matinas Biopharma Competitors ObsEva Competitors AEON Biopharma Competitors NeuroBo Pharmaceuticals Competitors Spruce Biosciences Competitors Aeterna Zentaris Competitors China Pharma Competitors Graybug Vision Competitors Oragenics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TZAC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenzing Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenzing Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access